Medical Watch Disease & Treatment News

Blood-based biomarkers are driving a shift toward earlier, more accurate Alzheimer's diagnosis across care settings.

• In secondary care, BBM...

A new systematic review and meta-analysis of 43 RCTs (N=23,209) found multidomain interventions combining diet, exercise, and cognitive training...

Recent pharmacological advances for congenital adrenal hyperplasia show promise in improving control while lowering glucocorticoid exposure.

-...

A real-world LEADER study found 82.5% of early Alzheimer's patients on Leqembi remained stable or improved after 17 months, with consistent results...

IBC-Ab002 safely blocked PD-L1 briefly in the brain during a Phase 1b trial of 40 early Alzheimer’s patients, meeting its primary endpoint with no...

FDA accepts BioMarin's sNDA for full approval of VOXZOGO in children with achondroplasia, backed by the largest long-term dataset including adult height, body proportionality, and arm span outcomes. PDUFA target date is Feb. 28, 2027.

KCL-286, an oral RARβ agonist already cleared in Phase 1 human trials, repairs DNA double-strand breaks and reduces neuroinflammation in Alzheimer's...

A large study of 3,895 older adults links cumulative cortisol exposure to faster cognitive decline, while moderate daily variation appears...

WCC BIOMEDICAL's progress on automated mass production tackles the core 3A hurdles—adequate loading, accurate dosing, and scalable manufacturing—for...

Trispecific CAR T cells targeting CD19, CD20, and CD22 show early potential to overcome relapse driven by CD19 loss.

• 16 patients treated in...

Alzheimer's Treatment Advances

• 🔥 Leqembi At-Home Dosing: FDA approved a once-weekly subcutaneous Leqembi shot enabling at-home treatment for...

ApoE4, the strongest genetic risk factor for late-onset Alzheimer's, disrupts synaptic integrity by perturbing lipid metabolism, mitochondrial...

Biobanks paired with high-plex proteomics are unlocking earlier detection and targeted therapies at population scale.

• UK Biobank project identified...

• Discovered in 1990 at Gustave Roussy via subtraction hybridisation as a lymphocyte activation gene expressed on T and NK cells
• Functions as an...

Low oxygen therapy extended lifespan threefold and improved brain function in mice with HTRA2-related mitochondrial defects by curbing toxic oxygen...

Both anti-tau and anti-amyloid approaches are moving forward in Alzheimer's treatment.

• Biogen's diranersen missed its primary Phase 2 endpoint yet...

British researchers report early progress toward an HIV cure, building on the fact that current antiretroviral therapies control immune effects but offer no effective cure yet.

• AstraZeneca's dnTGFβRII-armored CAR T cells target TGFβ suppression to extend cell therapy beyond blood cancers into solid tumors.
• CAR-NK...

Gene therapy is moving from experimental promise to approved treatments and funded trials at an accelerating pace.

• FDA approval milestone: Otarmeni...

The EMA panel has backed orphan drug status for Vanda’s imsidolimab in generalized pustular psoriasis, offering new hope for this rare inflammatory skin condition.